Rare Cancers Australia hosted our latest Facebook Live
Q&A on May 15, 2018, with Professor Andrew Wilson, Chair of the
Pharmaceutical Benefits Advisory Committee (PBAC) which oversees the
Pharmaceutical Benefits Scheme (PBS) in Australia.
Unfortunately due to technical issues beyond our control the
video feed was lost. Presented here is the original introduction followed by
the full audio recording of that conversation.
Questions, Timestamps and Transcript
- Question 1 – How do the TGA, PBAC and PBS work and how are
drugs approved? (0:45)
- Question 2 – How does the PBAC deal with lack of data for
rare cancers? (7:46)
- Question 3 – Does the PBAC consider the cost of not funding a
- Information – On questions about specific drugs /
- Question 4 – How does information from other countries
inform the process and what affects priority in the approvals process? (12:45)
Question 5 – What can be done for drugs for multiple
- Question 6 – What is the potential for provisional
- Question 7 – What is the best way for the public to
assist the process? (25:54)
- Question 8 – What gives you the most hope? (30:44)
- Conclusion (33:18)
A full transcript is available here.
Like the Rare Cancers Australia Facebook Page so you don't
miss our next Live Q&A.